Korean J Ophthalmol.  2020 Feb;34(1):92-93. 10.3341/kjo.2019.0052.

A Case of Recurrent Vogt-Koyanagi-Harada Disease Successfully Treated with Adalimumab in Young Female Adult Patient

• Kwon HY
• Woo SJ

• KMID: 2469293
• DOI: http://doi.org/10.3341/kjo.2019.0052

Abstract

No abstract available.

MeSH Terms

Adalimumab*
Adult*
Female*
Humans
Uveomeningoencephalitic Syndrome*
Adalimumab

Figure

• 

  Fig. 1 (A) 11 months before the treatment of adalimumab. Color fundus photography showing sunset glow fundus changes with diffuse Dalen-Fuchs nodules, consistent with Vogt-Koyanagi-Harada disease. (B) Optical coherencetomography showing mild choroidal thickening without subretinal fluid. (C) Ant seg photo showing posterior synechiae on lens before adalimumab treatment. (D) One month before the treatment of adalimumab. Color fundus photography showing aggravated chorioretinal atrophy threatening the posterior pole. (E) 15 months after the treatment of adalimumab. Color fundus photography showing stopped progression of chorioretinal atrophy.

Reference

1. Greco A, Fusconi M, Gallo A, et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev. 2013; 12:1033–1038.

2. Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016; 375:932–943.

3. Couto C, Schlaen A, Frick M, et al. Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2018; 26:485–489.

4. Jeroudi A, Angeles-Han ST, Yeh S. Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014; 45:332–334.

5. Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibition for ophthalmic indications: current status and outlook. BioDrugs. 2013; 27:347–357.